Skip to main content
Hofseth BioCare ASA logo

Hofseth BioCare ASA — Investor Relations & Filings

Ticker · HBC ISIN · NO0010598683 LEI · 5967007LIEEXZXGGEO44 OL Manufacturing
Open in API
Filings indexed 731 across all filing types
Latest filing 2025-11-07 Share Issue/Capital Cha…
Country NO Norway
Listing OL HBC

About Hofseth BioCare ASA

https://hofsethbiocare.no/

Hofseth BioCare ASA is a biotechnology company that develops and manufactures high-value nutritional ingredients from fresh Norwegian salmon off-cuts. Using a proprietary and patent-protected enzymatic hydrolysis process, the company gently extracts bioactive components, ensuring the preservation of their nutritional value. Its core products include soluble proteins (peptides), full-spectrum salmon oil, and marine calcium/collagen. These ingredients are utilized in clinically-proven finished products for both human nutrition and pet health markets, reflecting a commitment to sustainability and the full utilization of marine resources.

Recent filings

Filing Released Lang Actions
Hofseth BioCare ASA: Terms of the Subsequent Offering
Share Issue/Capital Change Classification · 1% confidence The document is an announcement regarding the terms of a 'Subsequent Offering' of new shares by Hofseth BioCare ASA. It details the subscription period, the number of shares, the record date, and the conditions for the offering. While it mentions that a prospectus will be published later, this specific document is an announcement of the offering terms rather than the prospectus itself. As it pertains to the issuance of new shares and capital structure changes, it falls under the 'Share Issue/Capital Change' category.
2025-11-07 English
Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT - Attachment: HBC Q3 2025 Financial Report.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Third Quarter 2025 Financial Report' and contains comprehensive financial statements, including a consolidated statement of comprehensive income, statement of financial position, and cash flow statement for the interim period. It also includes a CEO statement, financial review, and notes to the financial statements. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-11-07 English
Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT
Earnings Release Classification · 1% confidence The document is titled 'THIRD QUARTER 2025 FINANCIAL REPORT' and provides a summary of financial performance, EBITDA, and operational highlights. Although it contains a concluding sentence stating 'Please find the HBC Q3 2025 Financial Report attached', the document itself contains the actual financial data, performance metrics, and operational highlights for the quarter, rather than being a mere notification of a report's existence. Therefore, it is classified as an Interim/Quarterly Report. Q3 2025
2025-11-07 English
Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING - Attachment: HBC - Notice of EGM.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an official 'Notice of Extraordinary General Meeting' (Innkalling til ekstraordinær generalforsamling) for Hofseth BioCare ASA. It outlines the agenda, voting procedures, and proposed resolutions for shareholders. While it contains information about a private placement and capital increase, these are the specific items to be voted upon at the meeting. Therefore, it is a proxy solicitation document intended to inform shareholders and request their participation/votes for the upcoming meeting.
2025-10-30 Norwegian
Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
AGM Information Classification · 1% confidence The document is a formal notice calling for an Extraordinary General Meeting (EGM) to approve the issuance of new shares related to a private placement. It provides the date, time, and location of the meeting, and outlines the agenda items. This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to participate in and vote at the upcoming meeting.
2025-10-30 English
Hofseth BioCare ASA: Mandatory Notification of Trade - Attachment: PDMR notification form Hofseth International AS.pdf
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or their close associate, specifically identifying 'Hofseth International AS' as a close associate to a board member. It follows the standard regulatory template for disclosing insider dealings, including details of the issuer, the nature of the transaction (share allocation), price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.